Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
SAN DIEGO, Nov. 8, 2012
SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will present a company overview at three
investor conferences November 13 - 15. These three corporate presentations
will be webcast.
Tuesday, November 13^th at 1:30 p.m. Eastern Time: Lazard Capital Markets 9^th
Annual Healthcare Conference in New York City
Thursday, November 15 ^ th at 3 p.m. Greenwich Mean Time: Jefferies 2012
Global Healthcare Conference in London
Thursday, November 15^th at 1:30 p.m. Mountain Time: Credit Suisse Healthcare
Conference in Phoenix
To listen to the live webcast or a replay of the presentations, please visit
the Investor Relations section of the Company's Web site at www.orexigen.com.
A replay will be available for 14 days after each event.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave^®,
which has completed Phase III clinical trials and for which a New Drug
Application has been submitted and reviewed by the FDA. The Company has also
reached agreement with the FDA on a Special Protocol Assessment (SPA) for the
Light Study, the Contrave cardiovascular outcomes trial. The Company's other
product candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.
Orexigen Contact: Media Contact:
McDavid Stilwell Denise Powell
VP, Corporate Communications and Business Development WCG
(858) 875-8629 (510) 703-9491
SOURCE Orexigen Therapeutics, Inc.
Press spacebar to pause and continue. Press esc to stop.